Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rafael Rosell, MD"'
Autor:
Carlos Pedraz-Valdunciel, PhD, Masaoki Ito, MD, Stavros Giannoukakos, PhD student, Ana Giménez-Capitán, MSc, Miguel Ángel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100604- (2023)
Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are st
Externí odkaz:
https://doaj.org/article/d9bf3f77370d44da9f2f5fc06d7d9205
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100571- (2023)
Externí odkaz:
https://doaj.org/article/4e8aa2e805e5405cb9429449246317b2
Autor:
Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz:
https://doaj.org/article/08a2152e29af4e089606394482732718
Autor:
Masaoki Ito, MD, Jordi Codony-Servat, PhD, Ana Giménez-Capitán, BSc, Mireia Serra-Mitjans, MD, Francisco Pérez-Ochoa, MD, David Llige, BSc, Imane Chaib, PhD, Ramón Rami-Porta, MD, Carme Obiols, MD, Sergi Call, MD, Manuela Iglesias, MD, José Belda-Sanchis, MD, Xavier Tarroch-Sarasa, MD, Niki Karachaliou, MD, Miguel Angel Molina-Vila, PhD, Morihito Okada, MD, Rafael Rosell, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100084- (2020)
Introduction: EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be p
Externí odkaz:
https://doaj.org/article/ba1595860e4f4a8a8b44fa1c6caeb13a